Synergistic effects of combining PARP inhibitor (AZD2281) and ATR inhibitor (AZD6738) in Ewing Sarcoma cell lines
Ewing Sarcoma (ES) is an aggressive pediatric solid tumor. Even though overall-survival for localized patients is approximately 70%, the overall-survival for high risk ES patients has not improved in the last 20 years. Therefore, there is a need for exploration of new therapeutic agents in ES. Recen...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/30818 |